Two Fish-Oil Candidates Fail Late-Stage Tests Two Fish-Oil Candidates Fail Late-Stage Tests

AstraZeneca stops trial of omega-3 carboxylic acids (Epanova) for mixed dyslipidemia; Acasti Pharma trial of omega-3 phospholipid (CaPre) fails to meet end point in severe hypertriglyceridemia.Medscape Medical News

Source: Medscape Internal Medicine Headlines - January 15, 2020 Category: Internal Medicine Tags: Cardiology News Source Type: news